November 2021 Vaccination Update

We have written to National Immunisation Advisory Committee (NIAC) to highlight the additional risks faced by people with Down syndrome if they contract Covid 19,  and we are pleased to be able to let you know that people aged 16-59 years who have an underlying condition, which includes adults with Down syndrome, will be prioritised for a booster dose of the Pfizer or Moderna vaccine.

The HSE is still working on the implementation of the new recommendations. Timelines will be shared when we have them, but will partly depend on when people received their second dose of the vaccine, as they cannot be offered the additional dose until five to six months afterwards.

The third dose will also need to be delayed if a person has had laboratory-confirmed COVID-19 infection since vaccination. In this case, the booster dose will need to be delayed until at least six months after the COVID-19 infection was diagnosed.

NIAC have strongly recommended that those who have not yet received their primary vaccination do so as a matter of urgency given the current level of infection in the community, and knowing the additional risks from Covid 19 infection faced by adults with Down syndrome, we would strongly support this position.